There is no Pap smear equivalent for ovarian cancer, and that absence is a big part of why the disease remains the deadliest gynecologic cancer in the United States. Ovarian cancer ranks as the second most common gynecologic cancer nationally, but it carries the highest death rate of any of them, and it's among the leading causes of cancer death in women overall, trailing only lung and breast cancer.
According to the American Cancer Society, more than 21,000 women in the U.S. will be diagnosed with ovarian cancer in 2026, and an estimated 12,000 will die from it. As ClickOnDetroit reported, most women are diagnosed only after the disease has already reached an advanced stage, since there is currently no early detection test available. Michigan Ovarian Cancer Alliance executive director Megan Neubauer joined the station's Local 4 Live to walk through what women need to know and what's being done statewide to close that gap.
Ovarian cancer remains a concern in Michigan. Symptoms like bloating, pelvic pain, and urinary urgency can be common, and ovarian cancer often spreads early.
Why Survival Odds Hinge on Timing
The stakes of that delay are clear: most women are diagnosed only after the disease has already reached an advanced stage.
It might seem logical, then, to ask whether routine screening could be a fix.
Prevention Shifts Toward Genetics
Prevention also turns to inherited risk.
Genetics play a major role as well. Up to 20% of ovarian cancer cases stem from inherited mutations, and BRCA1 or BRCA2 gene mutations increase ovarian cancer risk, according to the American Association for Cancer Research. That statistic underscores why genetic counseling and family history assessment have become central to targeted prevention efforts rather than blanket screening.
On the treatment side, PARP inhibitors are discussed in the context of epithelial ovarian cancer, according to Contemporary OB/GYN. Nationally, overall ovarian cancer mortality has declined 45% since 1976, a trend the American Cancer Society attributes largely to historical increases in oral contraceptive use, decreased use of menopausal hormone therapy, and improved clinical treatments.
Michigan's Awareness Push and Patient Support
Locally, the Michigan Ovarian Cancer Alliance is using September's National Ovarian Cancer Awareness Month to mobilize volunteers statewide for its Tie Michigan Teal campaign, attaching teal ribbons and educational symptom cards to public landmarks around the state. The group also funds Michigan-based research through its annual $50,000 Geri Fournier Ovarian Cancer Research Grant, named for the alliance's co-founder; the 2025 recipient was Dr. Abdulsalam Soofi at the University of Michigan, as reported by The Eastern Echo.
Beyond awareness and research, the alliance runs the Angel Fund Financial Assistance Program, which distributes prepaid financial assistance cards to Michigan residents currently in or recently out of ovarian cancer treatment. The Angel Fund is among the alliance's patient support efforts. Experts say more work is still needed on the disease, and until an early detection test exists, campaigns like these remain among the few tools available for catching symptoms sooner and easing the burden on patients already in treatment.
